5 developments in orthobiologics


Here are five updates in the orthobiologics industry since Oct. 17:

1. Ossio closed a $38.5 million in financing to help accelerate adoption of the Ossiofiber intelligent bone regeneration technology.

2. Janet Conway, MD, completed the first U.S. cases using Bonesupport's Cerament G for osteomyelitis.

3. Bone Biologics and the University of California Los Angeles plan to begin their joint venture clinical trial testing the efficacy of their bone graft substitute treatment for spinal fusion, trauma, osteoporosis and other bone-related indications in 2023.

4. Swedish-based bone graft substitute manufacturer Bonesupport found its Cerament G can save patients an average $28,000.

5. Shriners Children's Hawaii in Honolulu is the first hospital in the state to use the Bridge-Enhanced ACL Restoration, or BEAR, implant.

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Podcast

Featured Whitepapers